… compared with single-agent chemotherapy in patients who acquired resistance to
erlotinib/gefitinib … afatinib in a greater than or equal to third-line setting, ≥12 weeks of disease …

… objective was altered to compare the efficacy between docetaxel and erlotinib in EGFR wild-type
… We summarized the main results of trials comparing second- or third-line chemotherapy …

… a potential predictive factor for gefitinib efficacy. As of August … trials comparing gefitinib to
platinum-based chemotherapy in … (gefitinib or erlotinib) as second- or third-line treatment after …

… , we designed this randomized, phase-2 study comparing the efficacy and tolerability of
erlotinib 100 mg/d vs. gefitinib 250 mg/d in patients with EGFR-mutated advanced NSCLC. …

… gefitinib in 2004 and erlotinib in 2007 as second-line therapy for pretreated lung adenocarcinoma
and third-line therapy … evaluate the difference in the efficacy of erlotinib and gefitinib in …

… ) compared with placebo as a third-line or subsequent therapy in patients with non-small cell
lung cancer (… The most frequently used EGFR TKIs were gefitinib, erlotinib, and icotinib. For …

… as third-line treatment agent in non-oncogene driven … In the univariate analysis, there was
a significant difference in the … ), such as gefitinib, afatinib, and erlotinib, are recommended …

… comparing with chemotherapy as second/third-line therapy 27,28 , one phase III RCT comparing
with targeted drugs as second/third-line therapy … , such as gefitinib and erlotinib. To date…

… efficacy and safety of pemetrexed versus pemetrexed + … the same level of difference reached
for therapy with erlotinib, at … But, the fact that there exists no established third-line treatment …

… agent in second- and third-line therapy is well established [9]. … aimed to evaluate the efficacy
of BE as first-line treatment and … Comparison of four chemotherapy regimens for advanced …